← All trials
NCT04552483
Phase 2Interventional
Includes controlled clinical studies conducted to evaluate the effectiveness of the drug for a particular indication or indications in participants with the disease or condition under study and to determine the common short-term side effects and risks.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Jun 8, 2020
- Primary completion
- Aug 20, 2020
- Completion date
- Sep 5, 2020
- First posted
- Sep 17, 2020
- Last posted
- Nov 3, 2020
- Enrollment
- 392
- Arms / groups
- 2 / —
- Source
- AACT · ingestion pipeline
Sponsors
- Federal University of Rio de JaneiroLead sponsor
- Government of BrazilCollaborator
- Federal University of Rio de JaneiroReponsible party - principal investigator
- Federal University of Rio de JaneiroOverall official - principal investigator
- Hospital de Transplante Doutor Euryclides de Jesus ZerbiniCollaborator
- ATCGenCollaborator
- Complexo Hospitalar Municipal de São Caetano do SulCollaborator
- National Research Council, BrazilCollaborator
- Hospital e Maternidade Therezinha de JesusCollaborator
- University of SorocabaCollaborator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.